References
- Surveillance, Epidemiology, and End Results Program . Cancer Stat Facts: Stomach Cancer. Available on: https://seer.cancer.gov/statfacts/html/stomach.html (Accessed on 17January2022).
- Surveillance, Epidemiology, and End Results Program . Cancer Stat Facts: Esophageal Cancer. Available on: https://seer.cancer.gov/statfacts/html/esoph.html (Accessed on 17January2022).
- GBD 2017 Stomach Cancer Collaborators . The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol. Hepatol.5(1), 42–54 (2020).
- GBD 2017 Oesophageal Cancer Collaborators . The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol.5, 582–597 (2020).
- National Comprehensive Care Network . Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer Version 2.2022. Available on: www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (Accessed on 17Jan2022).
- National Comprehensive Care Network . Clinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal and Esophageal Junction Cancers Version 2.2022. Available on: www.nccn.org/guidelines/guidelines-detail?category=1&id=1433 (Accessed on 30March2022).
- Casak SJ , Fashoyin-AjeI, LemerySJet al. FDA approval summary: ramucirumab for gastric cancer. Clin. Cancer Res.21(15), 3372–3376 (2015).
- FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer (Accessed on 17January2022).
- FDA approves nivolumab in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal (Accessed on 17January2022).
- Fuchs CS , ShitaraK, DiBartolomeo Met al. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol.20(3), 420–435 (2019).
- Wilke H , MuroK, Van CutsemEet al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol.15(11), 1224–1235 (2014).
- Robert C . A decade of immune-checkpoint inhibitors in cancer therapy. Nat. Commun.11(1), 3801 (2020).
- Zhang Z , XieT, ZhangX, QiC, ShenL, PengZ. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: current evidence and future perspectives. Chin. J. Cancer Res.32(3), 287–302 (2020).
- Fuchs CS , DoiT, JangRWet al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol.4(5), e180013 (2018).
- FDA grants accelerated approval to pembrolizumab for advanced gastric cancer. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-advanced-gastric-cancer (Accessed on 15February2022).
- FDA approves pembrolizumab for esophageal or GEJ carcinoma. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma (Accessed on 15February2022).
- Kojima T , ShahMA, MuroKet al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol.38(35), 4138–4148 (2020).
- FDA approves pembrolizumab for advanced esophageal squamous cell cancer. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-advanced-esophageal-squamous-cell-cancer (Accessed on 2March2022).
- Kato K , ChoBC, TakahashiMet al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol.20(11), 1506–1517 (2019).
- FDA approves nivolumab for esophageal squamous cell carcinoma. Available on: www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma (Accessed on 2March2022).
- Sun JM , ShenL, ShahMAet al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet398(10302), 759–771 (2021).
- Janjigian YY , KawazoeA, YanezPet al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature600(7890), 727–730 (2021).
- FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma. Available on: www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-trastuzumab-fluoropyrimidine (Accessed on 15February2022).
- Janjigian YY , ShitaraK, MoehlerMet al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet398(10294), 27–40 (2021).
- Paydary K , ReizineN, CatenacciDVT. Immune-checkpoint inhibition in the treatment of gastro-esophageal cancer: a closer look at the emerging evidence. Cancers (Basel)13(23), 5929 (2021).
- Catenacci DV , ChaoJ, MuroKet al. Toward a treatment sequencing strategy: a systematic review of treatment regimens in advanced gastric cancer/gastroesophageal junction adenocarcinoma. Oncologist26(10), e1704–e1729 (2021).
- Li SS , KlempnerSJ, CostantinoCLet al. Impact of treatment sequencing on survival for patients with locally advanced gastric cancer. Ann. Surg. Oncol.28(5), 2856–2865 (2021).
- Kankeu Fonkoua LA , ChakrabartiS, SonbolMBet al. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int. J. Cancer149(2), 378–386 (2021).
- Sasaki A , KawazoeA, EtoTet al. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open4(Suppl. 2), e000775 (2020).
- Kawai S , FukudaN, YamamotoSet al. Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. BMC Cancer20(1), 338 (2020).
- Kim R , TanA, ChoiM, El-RayesBF. Geographic differences in approach to advanced gastric cancer: is there a standard approach?Crit. Rev. Oncol. Hematol.88(2), 416–426 (2013).
- Ma X , LongL, MoonS, AdamsonBJS, BaxiSS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. MedRxiv, 10.1101/2020.03.16.20037143 (2020).
- Birnbaum B , NussbaumN, Seidl-RathkopfKet al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. ArXiv., Doi: 10.48550/arXiv.2001.09765 (13 January 2020). Available on: https://arxiv.org/abs/2001.09765
- National Comprehensive Care Network . Clinical Practice Guidelines in Oncology (NCCN Guidelines). Esophageal and Esophageal Junction Cancers Version 1.2022. Available on: www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf (Accessed on 17January2022).
- Kim J , ByeonS, KimHet al. Impact of prior ramucirumab use on treatment outcomes of checkpoint inhibitors in advanced gastric cancer patients. Target Oncol.15(2), 203–209 (2020).
- Barzi A , HessLM, ZhuYEet al. Real-world outcomes and factors associated with the second-line treatment of patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Cancer Control26(1), Doi: 10.1177/1073274819847642 (2019).